Comparative Pharmacology
Head-to-head clinical analysis: KENACORT versus SYNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENACORT versus SYNACORT.
KENACORT vs SYNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis; suppresses cytokine production and immune cell migration.
Synthetic corticosteroid with potent glucocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
Kenacort (triamcinolone acetonide) is a corticosteroid. For adults, typical dosing is 40-80 mg intramuscularly (deep intragluteal) as a single injection; oral tablets: 4-48 mg/day divided every 6-12 hours; intra-articular: 5-40 mg depending on joint size.
100 mg intravenously every 8 hours for 24 hours, then 50 mg intravenously every 8 hours for 48 hours, followed by 25 mg intravenously every 8 hours for 72 hours.
None Documented
None Documented
Terminal elimination half-life: 2-5 hours (triamcinolone acetonide). Clinical context: Short half-life supports alternate-day dosing for chronic conditions; however, adrenal suppression may persist longer.
Terminal elimination half-life is 2.5–3.5 hours; clinically, this short half-life requires multiple daily dosing for sustained effects.
Renal: 25-30% as unchanged drug and metabolites. Biliary/fecal: 50-70% as metabolites, with enterohepatic circulation.
Primarily renal (80% as metabolites, 20% unchanged); minor biliary/fecal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid